Lexicon Pharmaceuticals (LXRX) Non-Current Assets (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Non-Current Assets data on file, last reported at $82.8 million in Q1 2026.

• On a quarterly basis, Non-Current Assets rose 59.62% year-over-year to $82.8 million in Q1 2026; TTM through Mar 2026 was $329.8 million, a 57.7% increase from a year earlier, with the FY2025 full-year figure at $83.1 million, up 59.1% from the prior year.
• Non-Current Assets for Q1 2026 stood at $82.8 million, roughly flat from $83.1 million in the prior quarter.
• Over the last five years, Non-Current Assets for LXRX reached as high as $83.4 million in Q3 2025 and fell as low as $47.4 million in Q2 2022.
• Historically, Non-Current Assets has averaged $59.1 million across 5 years, with a median of $52.9 million in 2023.
• Across the five-year window, Non-Current Assets decreased 2.04% in 2022 and jumped 59.62% in 2026, its largest moves.
• Year by year, Non-Current Assets stood at $53.4 million in 2022, then declined by 1.03% to $52.9 million in 2023, then fell by 1.24% to $52.2 million in 2024, then surged by 59.1% to $83.1 million in 2025, then fell by 0.37% to $82.8 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $82.8 million in Q1 2026, $83.1 million in Q4 2025, and $83.4 million in Q3 2025.